{
    "200_day_moving_avg": {
        "title": "200-Day Moving Average",
        "value": "3.38"
    },
    "50_day_moving_avg": {
        "title": "50-Day Moving Average",
        "value": "4.08"
    },
    "52_week_change": {
        "title": "52-Week Change",
        "value": "151.85%"
    },
    "52_week_high": {
        "title": "52 Week High",
        "value": "6.10"
    },
    "52_week_low": {
        "title": "52 Week Low",
        "value": "1.89"
    },
    "company_name": {
        "title": "Company Name",
        "value": "Fortress Biotech, Inc. (FBIO)"
    },
    "float": {
        "title": "Float",
        "value": "58.03M"
    },
    "fullTimeEmployees": {
        "title": "Profile",
        "value": 111
    },
    "held_by_insiders": {
        "title": "% Held by Insiders",
        "value": "28.85%"
    },
    "held_by_institutions": {
        "title": "% Held by Institutions",
        "value": "34.48%"
    },
    "industry": {
        "title": "Industry",
        "value": "Biotechnology"
    },
    "profile": {
        "title": "Profile",
        "value": "Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in New York, New York."
    },
    "sector": {
        "title": "Sector",
        "value": "Healthcare"
    },
    "shares_outstanding": {
        "title": "Shares Outstanding",
        "value": "94.88M"
    },
    "shares_short": {
        "title": "Shares Short (Mar 15, 2021)",
        "value": "1.45M"
    },
    "short_percent_of_float": {
        "title": "Short % of Float (Mar 15, 2021)",
        "value": "2.00%"
    },
    "short_percent_of_shares_outstanding": {
        "title": "Short % of Shares Outstanding (Mar 15, 2021)",
        "value": "1.52%"
    },
    "short_ratio": {
        "title": "Short Ratio (Mar 15, 2021)",
        "value": "0.98"
    }
}